1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,270 | 0,310 | 23:01 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Sprint Bioscience AB: Sprint Bioscience completes strategic STK25 evaluation; continued focus on the primary indication | 114 | GlobeNewswire (Europe) | Sprint Bioscience AB (publ) today announces the conclusion of a targeted evaluation of the STK25 program, conducted in partnership with the Experimental Drug Development Centre (EDDC), Singapore's national... ► Artikel lesen | |
| 01.04. | Sprint Bioscience AB: Sprint Bioscience appoints Jenni Björnulfson as CFO | 124 | GlobeNewswire (Europe) | Sprint Bioscience AB (publ) today announces that Jenni Björnulfson has been appointed chief Financial Officer (CFO) of the company. With extensive and diverse experience in both life science and finance... ► Artikel lesen | |
| 01.04. | Sprint Bioscience AB: Positive results expand the NNMT program into Chronic Kidney Disease | 108 | GlobeNewswire (Europe) | Sprint Bioscience AB (publ) today announces positive results from its NNMT program from a proof-of-concept study demonstrating therapeutic potential in Chronic Kidney Disease (CKD). Based on these findings... ► Artikel lesen | |
| SPRINT BIOSCIENCE Aktie jetzt für 0€ handeln | |||||
| 17.03. | Sprint Bioscience AB: Sprint Bioscience reports positive results from the VRK1 program | 153 | GlobeNewswire (Europe) | Sprint Bioscience AB (publ) today announces positive results from a pre-clinical proof-of-concept (POC) study performed within the company's VRK1 program. The results show that VRK1 inhibition selectively... ► Artikel lesen | |
| 24.11.25 | Sprint Bioscience Announces Sale Of TREX1 Program to Gilead Sciences | 796 | AFX News | FOSTER CITY (dpa-AFX) - Sprint Bioscience AB (SPRINT.ST) announced the sale of its TREX1 cancer program to Gilead Sciences. The deal includes an upfront payment of $14 million, as well as potential... ► Artikel lesen |
5 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PALATIN TECHNOLOGIES | 22,450 | +0,09 % | Morning Market Movers: Super Micro Computer, Bimergen Energy, Palatin Technologies, Intellicheck See Big Swings | HONG KONG (dpa-AFX) - At 7:40 a.m. ET on Friday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 1,560 | +0,65 % | Cosciens Biopharma Inc: Cosciens Biopharma to exit U.S. reporting | ||
| HALOZYME THERAPEUTICS | 58,28 | -0,14 % | Vertex Licenses Halozyme's Hypercon Technology For Use In Up To Three Drug Targets | CAMBRIDGE (MASSACHUSETTS) (dpa-AFX) - Halozyme Therapeutics (HALO) announced its subsidiary, Halozyme Hypercon, entered into a global exclusive collaboration and license agreement with Vertex... ► Artikel lesen | |
| ABCELLERA BIOLOGICS | 3,555 | +4,56 % | Truist reiterates Buy on AbCellera stock ahead of 2H26 data | ||
| GLOW LIFETECH | 0,027 | 0,00 % | Glow Lifetech Corp.: Glow Lifetech Reports Fourth Quarter and Full Year 2025 Financial Results; 146% YoY Revenue Growth and Second Consecutive Quarter of Positive Cash Flow | Toronto, Ontario--(Newsfile Corp. - April 8, 2026) - Glow Lifetech Corp. (CSE: GLOW) (OTCID: GLWLF) (FSE: 9DO) ("Glow" or the "Company") is pleased to report its financial results for the fourth... ► Artikel lesen | |
| BIO-RAD LABORATORIES | 256,40 | -1,38 % | Bio-Rad Laboratories Swings To Q4 Profit | WASHINGTON (dpa-AFX) - Bio-Rad Laboratories, Inc. (BIO), a life science and diagnostic company, on Thursday, reported strong financial performance for the fourth quarter and full year 2025.... ► Artikel lesen | |
| AVID BIOSERVICES | - | - | Avid Bioservices Announces Grand Opening of New Early Phase Center of Excellence in Costa Mesa, California | COSTA MESA, Calif., Feb. 24, 2026 /PRNewswire/ -- Avid Bioservices, Inc., a dedicated biologics CDMO, today announced the grand opening of its new Early Phase Center of Excellence, a state... ► Artikel lesen | |
| MINERVA NEUROSCIENCES | 6,040 | +1,43 % | Citizens initiates Minerva Neurosciences stock at outperform, $14 target | ||
| BIOLINERX | 1,720 | -1,71 % | BioLineRx Ltd.: BioLineRx Announces Initiation of Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM) | GLIX1, a TET2 activator, is a first-in-class, oral, small molecule targeting DNA damage response in glioblastoma and other cancers
GLIX1 has demonstrated potent... ► Artikel lesen | |
| WHITEHAWK THERAPEUTICS | 3,680 | +2,79 % | Whitehawk Therapeutics, Inc.: Whitehawk Therapeutics Presents Real-World Analysis Confirming MUC16 as a Highly Expressed, Clinically Relevant Target for Gynecologic Cancers at SGO 2026 | MUC16 is the highest-expressing ADC target in ovarian cancer, at least two-fold higher than other emerging targets
MUC16 is highly and stably expressed in the most... ► Artikel lesen | |
| PARATEK PHARMACEUTICALS | - | - | Paratek Pharmaceuticals: $1.3 Billion Financing Supports Radius Health Combination To Build Specialty Pharma Platform | ||
| OVID THERAPEUTICS | 2,420 | -0,82 % | H.C. Wainwright bestätigt Kaufempfehlung für Ovid Therapeutics | ||
| APPLIED THERAPEUTICS | 0,077 | 0,00 % | Cycle Pharmaceuticals Completes Acquisition of Applied Therapeutics | Cycle Group Holdings Limited ("Cycle") is delighted to announce it has completed the acquisition of NASDAQ-listed Applied Therapeutics, Inc. (NASDAQ: APLT; "Applied"), a clinical-stage biopharmaceutical... ► Artikel lesen | |
| COCRYSTAL | 1,200 | -3,23 % | Cocrystal Pharma, Inc.: Cocrystal Pharma Receives IRB Approval from Emory University School of Medicine for Phase 1b Human Challenge Study with CDI-988 for Prevention and Treatment of Norovirus | Subject enrollment expected to begin in Q1 2026CDI-988 is the first oral broad-spectrum antiviral drug candidate for potential prevention of norovirus outbreaks and treatment of acute viral gastroenteritis... ► Artikel lesen | |
| GEOVAX LABS | 1,150 | +0,88 % | EQS-News: GeoVax, Inc.: GeoVax Reports 2025 Year-End Financial Results and Provides Business Update | EQS-News: GeoVax, Inc.
/ Key word(s): Financial
GeoVax Reports 2025 Year-End Financial Results and Provides Business Update 15.04.2026 / 22:13 CET/CEST
The issuer is solely... ► Artikel lesen |
Das Unternehmen SPRINT BIOSCIENCE AB kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -4,93 % bei einem Aktienkurs von 0,270 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SPRINT BIOSCIENCE AB finden Sie auf Wallstreet Online.